RxDoctor Payments Data

Alexander Chan, MD

Internal Medicine · New York, NYNPI 1568427243

Payments from drug & device makers

$2,195in general payments, 2019–2025

Across 71 payments — averaging $30.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$786
  • Amarin Pharma, Inc.$314
  • Esperion Therapeutics, Inc.$284
  • Boehringer Ingelheim$228
  • GSK$182
  • Abbott$124
  • plus $276 from 6 others

What the payments were for

  • Food & beverage$2,17299%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,195 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$138,189
Medicare patients
154
Services billed
1,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol372$400,016
VascepaIcosapent Ethyl577$307,300
JanuviaSitagliptin Phosphate273$253,461
TradjentaLinagliptin175$152,690
JardianceEmpagliflozin163$145,786
Diclofenac Epolamine124$91,102
RybelsusSemaglutide63$78,835
XareltoRivaroxaban75$68,597
JanumetSitagliptin Phos/Metformin Hcl66$48,740
CreonLipase/Protease/Amylase41$44,076
MyrbetriqMirabegron44$34,625
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$34,056
EliquisApixaban37$30,678
Dexlansoprazole DrDexlansoprazole92$28,114
DapagliflozinDapagliflozin Propanediol50$27,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$37$415,873384 claims
Boehringer IngelheimTradjenta, Jardiance, Jentadueto, Combivent Respimat, Synjardy$228$337,896387 claims
Novo NordiskRybelsus, Ozempic$48$91,74477 claims
GSKTrelegy Ellipta, Anoro Ellipta, Shingrix, Arexvy$182$72,997163 claims
AbbVieCreon, Linzess$82$60,33564 claims
PfizerEliquis$15$30,67837 claims
GileadVemlidy$786$23,19316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →